市場調查報告書
商品編碼
1008076

乾燥症候群全球酸市場(2020-2026)

Global Sjogren's Syndrome Acids Market 2020-2026

出版日期: | 出版商: Orion Market Research Pvt Ltd | 英文 | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

乾燥症候群全球酸市場:按測試(驗血、眼科、成像和活檢)、按藥物類型(毛果芸香鹼、環孢素、羥氯奎、免疫抑製劑)、按類型(原發性乾燥症候群)、繼發性乾燥症候群),區域、市場規模預測、份額和趨勢分析報告

在預測期內,全球乾燥症候群市場預計將以 4.6% 的複合年增長率增長。乾燥症候群是一種人體免疫系統疾病,會影響身體產生唾液和眼淚等液體的部位。這是一種影響日常生活的長期病症,通常始於 40-60 歲,女性比男性更常見。乾燥症還會影響身體的其他部位,例如腎臟、關節、肺、神經和血管。治療的重點是緩解症狀,如乾眼症服用人工淚液、吸入無糖糖果、口乾多喝水、服用一些藥物。我有。促進市場增長的因素包括患有多種可導致乾燥症候群的疾病的人口不斷增加,以及對乾燥症候群先進治療的需求不斷增加。其他因素包括導致乾眼症的隱形眼鏡使用增加、採用不健康的生活方式、增加眼部疾病的先進治療,以及推動市場增長的類風濕性關節炎和狼瘡等疾病的發展。我有。

然而,公眾對乾燥症候群缺乏認識減緩了市場增長。預計進一步缺乏適當的治療也將阻礙市場增長。目前,可用的治療方案對以下綜合徵患者無效或只能緩解症狀:實驗室自動化程度的提高和技術進步為市場增長提供了機會。此外,北美類風濕性關節炎聯盟等政府舉措不斷加強,正在對醫療保健專業人員和患者進行診斷和治療方面的教育,從而推動乾燥綜合徵市場的增長。

分部展望

全球乾燥症候群市場根據測試、藥物類型和類型進行劃分。根據測試,市場分為血液測試、視力測試、成像測試和活組織檢查。根據藥物類型,市場分為毛果芸香鹼、環孢素、羥氯奎和免疫抑製劑。根據類型,市場分為原發性乾燥症候群和繼髮乾燥綜合徵。

按類型

繼發性乾燥症候群細分市場有望主導全球乾燥症候群市場

預計繼發性乾燥症候群將佔據全球乾燥症候群市場的很大份額。促進市場增長的因素包括類風濕性關節炎等自身免疫性疾病的患病率增加。繼發性乾燥症候群的最常見原因之一是類風濕性關節炎。這種類型的診斷包括原發性膽汁性膽管炎、狼瘡和硬皮病等症狀。對於繼發性乾燥症候群,醫生會檢查完整的病史並進行體檢。診斷通常包括血液檢測,尋找 Sjogren 特有的蛋白質和標記物。它還包括下唇活檢以尋找炎症細胞。

區域展望

全球乾燥症候群市場根據地區進一步細分,包括北美、歐洲、亞太等地區。北美和歐洲對全球乾燥症候群酸市場做出了重大貢獻。市場增長的主要驅動力是類風濕性關節炎和狼瘡等自身免疫性疾病的數量增加,對此類疾病的先進治療解決方案的需求不斷增加,以及該地區乾燥症候群的患病率不斷上升。我做到了。

亞太地區將經歷全球乾燥症候群市場的顯著增長

由於區域醫療保健基礎設施的不斷發展、乾燥症診斷的增加以及政府在醫療保健領域的支出增加,預計亞太地區乾燥症候群市場將出現快速增長。根據 Sage 2019 年發表的報告,近 68.59% 的中國患者患有乾眼症,86.5% 的中國患者患有口乾症,6.9% 的中國患者患有關節炎。此外,乾燥症候群的日益流行和此類診斷的增加也推動了市場增長。然而,缺乏適當的治療選擇、缺乏認識和負擔能力是阻礙中東和非洲等發展中國家市場增長的因素。

市場參與者展望

乾燥症候群市場的主要參與者包括 AbbVie Inc.、Amgen Inc.、Argentis Pharmaceuticals, LLC、AstraZeneca PLC 等。市場參與者通過採用包括合併、收購、合作和新產品發佈在內的各種策略來保持市場競爭力,為市場增長做出了重大貢獻。例如,2020 年 7 月,UniQuest 與 CSL Ltd 合作開發和商業化用於治療乾燥症候群的抗原免疫耐受誘導技術。這項合作研究的主要目的是確定封裝在乾燥症候群脂質體中的抗原候選物,並使其成為臨床試驗的主要候選物。這項技術有可能治療患有自身免疫性疾病的患者。

本報告涵蓋以下項目

  • 市場價值數據分析和預測。
  • 每個細分市場的年市場收入(以 100 萬美元為單位)。
  • 主要地理區域的國家分析。
  • 在全球氯甲烷市場運營的主要公司。根據數據的可用性,報告中還提供了與新產品發佈和相關新聞相關的信息。
  • 通過確定未來強勁增長的關鍵細分市場來分析業務戰略。
  • 市場進入和市場擴張策略分析。
  • 通過確定誰在市場上的位置來製定競爭策略。

本報告調查了乾燥症候群的全球市場,概述了市場,分析了市場增長和障礙、市場機會、市場規模趨勢和按測試/藥物類型/類型/區域和競爭的預測。我們提供系統的主要公司的情況和簡介等信息。

目錄

第 1 章報告概述

第 2 章市場概覽和洞察

  • 調查範圍
  • 分析師洞察和當前市場趨勢
  • 規則

第 3 章市場決定因素

  • 動機
  • 抑制要因
  • 市場機會

第 4 章市場細分

  • 按藥物類型
    • 毛果芸香鹼
    • 環孢素
    • 羥氯奎
    • 免疫抑製劑
  • 按類型
    • 原發性乾燥症候群
    • 繼發性乾燥症候群

第 5 章區域分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 意大利
    • 西班牙
    • 法國
    • 其他歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 其他亞太地區
  • 其他領域

第 6 章公司簡介

  • AbbVie Inc.
  • Amgen Inc.
  • Argentis Pharmaceuticals, LLC
  • AstraZeneca PLC
  • Aldeyra Therapeutics, Inc.
  • Bristol-Myers Squibb Co.
  • Biogen Inc.
  • Demcon Hemics BV.
  • Daiichi Sankyo Co., Ltd.
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Horizon Therapeutics Plc
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • ONO PHARMACEUTICAL CO., LTD
  • Pfizer Inc.
  • Sanofi S.A.
目錄
Product Code: OMR2023369

Global Sjogren's Syndrome Acids Market Size, Share & Trends Analysis Report by Test (blood test, Eye test, imaging test, and Biopsy), By Drug Type (Pilocarpine, Cyclosporine, Hydroxychloroquine, and Immunosuppressive Agents), Type (Primary Sjogren's Syndrome, Secondary Sjogren's Syndrome) and Forecast 2021-2027

Global Sjogren's Syndrome market is anticipated to grow at a CAGR of 4.6% during the forecast period. Sjogren's syndrome is a disorder of the human immune system whereby it affects the parts of the body that produces fluids such as saliva, tears. It's a long- term condition that affects one's daily life and is more common in women than men that usually starts at age 40 to 60. Sjogren also affects the other parts of the body such as kidneys, joints, lungs, nerves, blood vessels. The treatment focuses on relieving the symptoms such as fiving artificial tears for dry eyes, sucking sugar free candies and drinking gallons of water for dry mouth along with taking some medicines. The factors contributing to the market growth include a growing population with several diseases that can cause Sjogren's syndrome and increasing demand for advanced treatment for Sjogren's syndrome. Other factors include increased use of contact lens that leads to dryness of eyes, unhealthy lifestyle adoption, increased advanced treatment of eye diseases and growing diseases like rheumatoid arthritis and lupus are propelling the growth of the market.

However, a lack of awareness among the population about Sjogren's syndrome restrains the growth of the market. Further lack of proper cure treatments is also projected to hamper the growth of the market. Currently, available treatment options are either ineffective in patients with the following syndrome or only relieve the symptoms. Increasing lab automation rates and technological advances will bring upon opportunities for the growth of the market. Additionally, rising government initiatives such as the North American Rheumatoid Arthritis consortium are educating healthcare professionals and patients regarding the diagnosis and its treatment will boost the growth of the Sjogren's syndrome market.

Segmental Outlook

The global Sjogren's syndrome market is segmented based on the test, drug type and type. based on test market are segmented blood test, Eye test, imaging test and biopsy. Based on a Drug type, the market is segmented into pilocarpine, cyclosporine, hydroxychloroquine, and immunosuppressive agents. On the basis of type, the market is segmented into primary Sjogren's syndrome and secondary Sjogren's syndrome.

Global Sjogren's Syndrome Market Share by Type, 2020(%)

Source: OMR Global

Secondary Sjogren's Syndrome Segment is Anticipated to Dominate the Global Sjogren's Syndrome Market

Secondary Sjogren's Syndrome is projected to hold a significant share in the global Sjogren's Syndrome market. The factors contributing to the market growth include the growing prevalence of autoimmune diseases such as rheumatoid arthritis. One of the most common causes of secondary Sjogren's syndrome include rheumatoid arthritis. This kind of diagnosis has the following conditions including primary biliary cholangitis, lupus, scleroderma and others. In secondary Sjogren's syndrome, the doctor will be going through complete medical history and conduct a physical exam. The diagnosis will be including blood work that usually looks for proteins and markers specific to Sjogren's. It also includes a lower lip biopsy to look for clusters of inflammatory cells.

Regional Outlook

The global Sjogren's Syndrome Market is further segmented based on geography including North America, Europe, Asia-Pacific, and the Rest of the World. North America and Europe have a significant contribution to the global Sjogren's Syndrome acid market. The growth of the market mainly driven due to the increasing number of autoimmune diseases such as rheumatoid arthritis, lupus, growing demand for advanced treatments solutions for such diseases and increasing prevailing rates of Sjogren's syndrome in the region.

Source: OMR Global

Asia-Pacific will Have Considerable Growth in the Global Sjogren's Syndrome Market

Asia Pacific region is forecasted to exhibit rapid growth of Sjogren's syndrome market due to rising healthcare infrastructure in the region, the rise of diagnosis of Sjogren's disease, and increasing government expenditure in the healthcare sector are driving the growth of the Sjogren's syndrome market in the region. According to Sage publications 2019, almost 68.59% of Chinese patients had dry eye prevalence, and 86.5% had dry mouth prevalence in Chinese patients additionally 6.9% of Chinese patients had arthritis. Further, the increasing prevalence of Sjogren's syndrome and the rise of such diagnosis also drive the growth of the market. However, lack of proper treatment options, lack of awareness and affordability are the factors restraining the growth of the market in underdeveloped countries such as the Middle East and Africa.

Market Players Outlook

The key players of the Sjogren's Syndrome market include AbbVie Inc., Amgen Inc., Argentis Pharmaceuticals, LLC, AstraZeneca PLC, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers, and acquisitions, collaborations, and new product launch, to stay competitive in the market. For instance, in July 2020, UniQuest partnered with CSL Ltd for developing and commercializing its antigen immune tolerance induction technology for treating Sjogren's syndrome. The main purpose of this collaboration was to identify liposome-encapsulated antigen candidates for Sjogren's syndrome and then shepherd the lead candidate towards its clinical trials. This technology has the potential to treat patients suffering from autoimmune diseases.

The Report Covers

  • Market value data analysis of 2020 and forecast to 2027.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global Sjogren's Syndrome Acids
  • market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Regulations

3. Market Determinants

  • 3.1. Motivators
  • 3.2. Restraints
  • 3.3. Opportunities

4. Market Segmentation

  • 4.1. Global Sjogren's Syndrome Market by Drug Type
    • 4.1.1. Pilocarpine
    • 4.1.2. Cyclosporine
    • 4.1.3. Hydroxychloroquine
    • 4.1.4. Immunosuppressive Agents
  • 4.2. Global Sjogren's Syndrome Market by Type
    • 4.2.1. Primary Sjogren's Syndrome
    • 4.2.2. Secondary Sjogren's Syndrome

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. AbbVie Inc.
  • 6.2. Amgen Inc.
  • 6.3. Argentis Pharmaceuticals, LLC
  • 6.4. AstraZeneca PLC
  • 6.5. Aldeyra Therapeutics, Inc.
  • 6.6. Bristol-Myers Squibb Co.
  • 6.7. Biogen Inc.
  • 6.8. Demcon Hemics BV.
  • 6.9. Daiichi Sankyo Co., Ltd.
  • 6.10. Eisai Co., Ltd.
  • 6.11. F. Hoffmann-La Roche Ltd.
  • 6.12. Horizon Therapeutics Plc
  • 6.13. Novartis AG
  • 6.14. Otsuka Pharmaceutical Co., Ltd.
  • 6.15. ONO PHARMACEUTICAL CO., LTD
  • 6.16. Pfizer Inc.
  • 6.17. Sanofi S.A.

LIST OF TABLES

  • 1. GLOBAL SJOGREN'S SYNDROME MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2020-2027 ($ MILLION)
  • 2. GLOBAL PILOCARPINE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 3. GLOBAL CYCLOSPORINE MARKET RESEARCH AND ANALYSIS BY TEST, 2020-2027 ($ MILLION)
  • 4. GLOBAL IMMUNOSUPPRESSIVE AGENTS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 5. GLOBAL HYDROXYCHLOROQUINE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 6. GLOBAL SJOGREN'S SYNDROME MARKET RESEARCH AND ANALYSIS BY TYPE 2020-2027 ($ MILLION)
  • 7. GLOBAL PRIMARY SJOGREN'S SYNDROME MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 8. GLOBAL SECONDARY SJOGREN'S SYNDROME MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 9. GLOBAL SJOGREN'S SYNDROME MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 10. NORTH AMERICAN SJOGREN'S SYNDROMEMARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 11. NORTH AMERICAN SJOGREN'S SYNDROMEMARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2020-2027 ($ MILLION)
  • 12. EUROPEAN SJOGREN'S SYNDROMEMARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 13. EUROPEAN SJOGREN'S SYNDROMEMARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2020-2027 ($ MILLION)
  • 14. ASIA-PACIFIC SJOGREN'S SYNDROMEMARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 15. ASIA-PACIFIC SJOGREN'S SYNDROMEMARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2020-2027 ($ MILLION)
  • 16. REST OF THE WORLD SJOGREN'S SYNDROMEMARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 17. REST OF THE WORLD SJOGREN'S SYNDROMEMARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2020-2027 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL SJOGREN'S SYNDROME MARKET SHARE BY TEST, 2020 VS 2027 (%)
  • 2. GLOBAL BLOOD TEST FOR SJOGREN'S SYNDROME MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 3. GLOBAL EYE TEST FOR SJOGREN'S SYNDROME MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 4. GLOBAL IMAGING TEST FOR SJOGREN'S SYNDROME MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 5. GLOBAL BIOPSY FOR SJOGREN'S SYNDROME MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 6. GLOBAL SJOGREN'S SYNDROMEMARKET SHARE BY DRUG TYPE, 2020 VS 2027 (%)
  • 7. GLOBAL PILOCARPINE FOR SJOGREN'S SYNDROME MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 8. GLOBAL CYCLOSPORINE FOR SJOGREN'S SYNDROME MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 9. GLOBAL HYDROXYCHLOROQUINE FOR SJOGREN'S SYNDROME MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 10. GLOBAL IMMUNOSUPPRESSIVE AGENTS FOR SJOGREN'S SYNDROME MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 11. GLOBAL SJOGREN'S SYNDROMEMARKET SHARE BY TYPE, 2020 VS 2027 (%)
  • 12. GLOBAL PRIMARY SJOGREN SYNDROME MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 13. GLOBAL SECONDARY SJOGREN SYNDROME MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 14. GLOBAL SJOGREN'S SYNDROME MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 15. GLOBAL PLATFORM SJOGREN'S SYNDROMEMARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 16. US SJOGREN'S SYNDROMEMARKET SIZE, 2020-2027($ MILLION)
  • 17. CANADA SJOGREN'S SYNDROMEMARKET SIZE, 2020-2027($ MILLION)
  • 18. UK SJOGREN'S SYNDROMEMARKET SIZE, 2020-2027($ MILLION)
  • 19. FRANCE SJOGREN'S SYNDROMEMARKET SIZE, 2020-2027($ MILLION)
  • 20. GERMANY SJOGREN'S SYNDROMEMARKET SIZE, 2020-2027($ MILLION)
  • 21. ITALY SJOGREN'S SYNDROMEMARKET SIZE, 2020-2027($ MILLION)
  • 22. SPAIN SJOGREN'S SYNDROMEMARKET SIZE, 2020-2027($ MILLION)
  • 23. REST OF EUROPE SJOGREN'S SYNDROMEMARKET SIZE, 2020-2027($ MILLION)
  • 24. INDIA SJOGREN'S SYNDROMEMARKET SIZE, 2020-2027($ MILLION)
  • 25. CHINA SJOGREN'S SYNDROMEMARKET SIZE, 2020-2027($ MILLION)
  • 26. JAPAN SJOGREN'S SYNDROMEMARKET SIZE, 2020-2027($ MILLION)
  • 27. SOUTH KOREA SJOGREN'S SYNDROMEMARKET SIZE, 2020-2027($ MILLION)
  • 28. REST OF ASIA-PACIFIC SJOGREN'S SYNDROMEMARKET SIZE, 2020-2027($ MILLION)
  • 29. REST OF THE WORLD SJOGREN'S SYNDROMEMARKET SIZE, 2020-2027($ MILLION)